NYSE · Healthcare

Bristol-Myers Squibb Company

BMY · Drug Manufacturers - General

$57.33

▼ -0.9 (-1.54%)

Data cached · refreshes every 10 min

Mr. Market is currently offering Bristol-Myers Squibb Company at $57.33.

The business passes only 2 of 7 of Graham's defensive criteria — well below his required standard.

Overall Grade

Defensive

Enterprising

Profitability A

Gross Profit Margin 71.1%

Operating Margin 28.5%

Net Income Margin 14.6%

Fin. Health D

Years to Pay Off Debt 6.7 yrs

Working Capital vs Long-Term Debt -$36.9B

Working Capital $6.0B

Valuation F

Margin of Safety 0.0%

Price-to-Book 6.34x

Cash Flow A

Free Cash Flow $12.8B

CapEx % of Net Income 18.6%

Owner Earnings $12.4B

2/7

Graham Score

Speculative

Defensive — Graham's strict criteria (P/B, P/E, dividends, stability) · Enterprising — Profitability & cash flow focused, accepts higher valuations for quality

Market Data

Market Cap $117.0B

Enterprise Value $154.9B

P/E (TTM) 16.06

Dividend Yield 4.29%

Exchange NYSE

Key Margins

Gross Profit 71.1%

Operating Margin 28.5%

Net Margin 14.6%

Company Info

Sector Healthcare

Industry Drug Manufacturers - General

Employees 32500

Country United States

Visit website

📖

Full Graham Analysis

Mr. Market is currently offering Bristol-Myers Squibb Company at $57.33.

The business passes only 2 of 7 of Graham's defensive criteria — well below his required standard.

At $57.33, the stock trades at a 116% premium to its Graham Number of $26.54. Graham would consider this price speculative.

There is no margin of safety at the current price. Graham would advise patience and waiting for a better entry point.

Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign..

Conclusion: By Graham's standards, this stock is speculative at its current price. The intelligent investor would look elsewhere or wait.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Showing Key Metrics

Income Highlights

Metric	2025	2024	2023	2022	2021
Gross Profit %	71.1% ▲	71.1%	76.2%	78.0%	N/A
Operating Margin %	28.5% ▲	12.2%	18.2%	19.7%	N/A
Net Income %	14.6% ▲	-18.5%	17.8%	13.7%	N/A
Diluted EPS	3.46 ▲	-4.41	3.86	2.95	N/A

Balance Sheet Highlights

Metric	2025	2024	2023	2022	2021
Total Assets	$90.0B	$92.6B	$95.2B	$96.8B	N/A
Total Debt	$47.1B ↓	$51.2B	$41.5B	$40.7B	N/A
Working Capital	$6.0B ▼	$6.0B	$9.5B	$5.4B	N/A
Years to Pay Debt	6.68	-5.72	5.17	6.44	N/A

Cash Flow Highlights

Metric	2025	2024	2023	2022	2021
Free Cash Flow	$12.8B ▼	$13.9B	$12.7B	$11.9B	N/A
Owner Earnings	$12.4B	$1.9B	$19.0B	$17.7B	N/A
CapEx % of Net Income	18.6%	N/A	15.1%	17.7%	N/A

Income Statement

	2025	2024	2023	2022	2021
Tax Effect Of Unusual Items	-1,148,422	-2,925,720	-41,031	-388,161
Tax Rate For Calcs	0	0	0	0
Normalized EBITDA	19,945,000	17,100,000	20,239,000	21,414,000
Total Unusual Items	-4,715,000	-13,932,000	-873,000	-2,193,000
Total Unusual Items Excluding Goodwill	-4,715,000	-13,932,000	-873,000	-2,193,000
Net Income From Continuing Operation Net Minority Interest	7,054,000	-8,948,000	8,025,000	6,327,000
Reconciled Depreciation	4,011,000	9,600,000	9,760,000	10,276,000
Reconciled Cost Of Revenue	13,242,000	13,240,000	9,980,000	9,456,000
EBITDA	15,230,000	3,168,000	19,366,000	19,221,000
EBIT	11,219,000	-6,432,000	9,606,000	8,945,000
Net Interest Income	-1,891,000	-1,947,000	-1,166,000	-1,232,000
Interest Expense	1,891,000	1,947,000	1,166,000	1,232,000
Normalized Income	10,620,578	2,058,280	8,856,969	8,131,839
Net Income From Continuing And Discontinued Operation	7,054,000	-8,948,000	8,025,000	6,327,000
Total Expenses	34,471,000	42,413,000	36,811,000	37,055,000
Diluted Average Shares	2,039,000	2,027,000	2,078,000	2,146,000
Basic Average Shares	2,034,000	2,027,000	2,069,000	2,130,000
Diluted EPS	0	0	0	0
Basic EPS	0	0	0	0
Diluted NI Availto Com Stockholders	7,054,000	-8,948,000	8,025,000	6,327,000
Net Income Common Stockholders	7,054,000	-8,948,000	8,025,000	6,327,000
Net Income	7,054,000	-8,948,000	8,025,000	6,327,000
Minority Interests	-2,000	-15,000	-15,000	-18,000
Net Income Including Noncontrolling Interests	7,055,000	-8,933,000	8,040,000	6,345,000
Net Income Continuous Operations	7,055,000	-8,933,000	8,040,000	6,345,000
Tax Provision	2,272,000	554,000	400,000	1,368,000
Pretax Income	9,328,000	-8,379,000	8,440,000	7,713,000
Other Income Expense	-2,504,000	-12,319,000	1,411,000	-159,000
Other Non Operating Income Expenses	2,211,000	1,613,000	2,284,000	2,034,000
Special Income Charges	-5,225,000	-14,426,000	-1,162,000	-1,563,000
Gain On Sale Of Business		-15,000	0	211,000	9,000
Other Special Charges	434,000	84,000	-390,000	444,000
Impairment Of Capital Assets		47,000	29,000	0	0
Restructuring And Mergern Acquisition	4,791,000	14,342,000	1,552,000	1,330,000
Earnings From Equity Interest			-160,000	-801,000	745,000
Gain On Sale Of Security	510,000	494,000	289,000	-630,000
Net Non Operating Interest Income Expense	-1,891,000	-1,947,000	-1,166,000	-1,232,000
Interest Expense Non Operating	1,891,000	1,947,000	1,166,000	1,232,000
Operating Income	13,724,000	5,887,000	8,195,000	9,104,000
Operating Expense	20,535,000	28,445,000	26,118,000	26,918,000
Depreciation Amortization Depletion Income Statement	3,317,000	8,872,000	9,047,000	9,595,000
Depreciation And Amortization In Income Statement	3,317,000	8,872,000	9,047,000	9,595,000
Amortization	3,317,000	8,872,000	9,047,000	9,595,000
Amortization Of Intangibles Income Statement	3,317,000	8,872,000	9,047,000	9,595,000
Research And Development	9,951,000	11,159,000	9,299,000	9,509,000
Selling General And Administration	7,267,000	8,414,000	7,772,000	7,814,000
Selling And Marketing Expense				7,814,000	7,690,000
General And Administrative Expense				7,814,000	7,675,000
Other Gand A				7,814,000	7,690,000
Salaries And Wages					-15,000
Gross Profit	34,259,000	34,332,000	34,313,000	36,022,000
Cost Of Revenue	13,936,000	13,968,000	10,693,000	10,137,000
Total Revenue	48,195,000	48,300,000	45,006,000	46,159,000
Operating Revenue	47,203,000	47,257,000	44,386,000	45,413,000

Balance Sheet

	2025	2024	2023	2022	2021
Treasury Shares Number	887,000	894,000	902,000	825,000
Preferred Shares Number	3	3	3	3
Ordinary Shares Number	2,035,753	2,029,000	2,021,000	2,075,000
Share Issued	2,922,753	2,923,000	2,923,000	2,900,000
Net Debt	34,902,000	39,303,000	28,308,000	30,197,000
Total Debt	47,139,000	51,200,000	41,464,000	40,717,000
Tangible Book Value	-22,634,000	-29,027,000	-19,224,000	-26,443,000
Invested Capital	63,584,000	65,984,000	69,202,000	70,381,000
Working Capital	5,973,000	6,006,000	9,508,000	5,383,000
Net Tangible Assets	-22,634,000	-29,027,000	-19,224,000	-26,443,000
Capital Lease Obligations	2,028,000	1,551,000	1,692,000	1,397,000
Common Stock Equity	18,473,000	16,335,000	29,430,000	31,061,000
Total Capitalization	61,323,000	63,938,000	66,083,000	66,117,000
Total Equity Gross Minority Interest	18,506,000	16,388,000	29,485,000	31,118,000
Minority Interest	33,000	53,000	55,000	57,000
Stockholders Equity	18,473,000	16,335,000	29,430,000	31,061,000
Gains Losses Not Affecting Retained Earnings	-1,523,000	-1,238,000	-1,546,000	-1,281,000
Other Equity Adjustments	40,000	378,000	4,000	232,000
Foreign Currency Translation Adjustments	-997,000	-968,000	-812,000	-890,000
Minimum Pension Liabilities	-566,000	-648,000	-738,000	-623,000
Treasury Stock	43,579,000	43,655,000	43,766,000	38,618,000
Retained Earnings	16,896,000	14,912,000	28,766,000	25,503,000
Additional Paid In Capital	46,387,000	46,024,000	45,684,000	45,165,000
Capital Stock	292,000	292,000	292,000	292,000
Common Stock	292,000	292,000	292,000	292,000
Total Liabilities Net Minority Interest	71,532,000	76,215,000	65,674,000	65,702,000
Total Non Current Liabilities Net Minority Interest	48,115,000	52,441,000	43,412,000	43,812,000
Other Non Current Liabilities	824,000	522,000	396,000	303,000
Employee Benefits	330,000	400,000	480,000	402,000
Non Current Pension And Other Postretirement Benefit Plans	330,000	400,000	480,000	402,000
Tradeand Other Payables Non Current	1,407,000	1,491,000	3,288,000	3,992,000
Non Current Deferred Liabilities	878,000	1,055,000	1,065,000	2,798,000
Non Current Deferred Revenue	169,000	230,000	300,000	283,000
Non Current Deferred Taxes Liabilities	222,000	369,000	338,000	2,166,000
Long Term Debt And Capital Lease Obligation	44,676,000	48,973,000	38,183,000	36,317,000
Long Term Capital Lease Obligation	1,826,000	1,370,000	1,530,000	1,261,000
Long Term Debt	42,850,000	47,603,000	36,653,000	35,056,000
Current Liabilities	23,417,000	23,774,000	22,262,000	21,890,000
Other Current Liabilities	13,072,000	12,907,000	11,498,000	10,566,000
Current Debt And Capital Lease Obligation	2,463,000	2,227,000	3,281,000	4,400,000
Current Capital Lease Obligation	202,000	181,000	162,000	136,000
Current Debt	2,261,000	2,046,000	3,119,000	4,264,000
Other Current Borrowings	2,261,000	2,046,000	3,119,000	4,264,000
Pensionand Other Post Retirement Benefit Plans Current	1,561,000	1,694,000	1,291,000	1,425,000
Payables And Accrued Expenses	6,321,000	6,946,000	6,192,000	5,499,000
Current Accrued Expenses	484,000	572,000	349,000	321,000
Interest Payable	484,000	572,000	349,000	321,000
Payables	5,837,000	6,374,000	5,843,000	5,178,000
Dividends Payable	1,283,000	1,258,000	1,213,000	1,196,000
Total Tax Payable	979,000	1,514,000	1,371,000	942,000
Income Tax Payable	979,000	1,514,000	1,371,000	942,000
Accounts Payable	3,575,000	3,602,000	3,259,000	3,040,000
Total Assets	90,038,000	92,603,000	95,159,000	96,820,000
Total Non Current Assets	60,648,000	62,823,000	63,389,000	69,547,000
Other Non Current Assets	2,201,000	2,123,000	1,148,000	752,000
Defined Pension Benefit	330,000	234,000	284,000	285,000
Non Current Deferred Assets	5,378,000	4,236,000	2,768,000	1,344,000
Non Current Deferred Taxes Assets	5,378,000	4,236,000	2,768,000	1,344,000
Non Current Accounts Receivable			436,000
Investments And Advances	2,507,000	2,508,000	2,499,000	2,187,000
Investmentin Financial Assets	411,000	772,000	800,000	0
Held To Maturity Securities	15,000	452,000	436,000	0
Available For Sale Securities	396,000	320,000	364,000		2,713,000
Long Term Equity Investment	2,096,000	1,736,000	1,699,000	2,187,000
Goodwill And Other Intangible Assets	41,107,000	45,362,000	48,654,000	57,504,000
Other Intangible Assets	19,353,000	23,643,000	27,485,000	36,355,000
Goodwill	21,754,000	21,719,000	21,169,000	21,149,000
Net PPE	9,125,000	8,360,000	8,036,000	7,475,000
Accumulated Depreciation	-5,293,000	-4,949,000	-4,803,000	-4,164,000
Gross PPE	14,418,000	13,309,000	12,839,000	11,639,000
Construction In Progress	1,619,000	1,525,000	1,075,000	1,053,000
Other Properties	1,582,000	1,224,000	1,390,000	1,220,000
Machinery Furniture Equipment	3,790,000	3,818,000	3,717,000	3,284,000
Buildings And Improvements	7,270,000	6,581,000	6,495,000	5,920,000
Land And Improvements	157,000	161,000	162,000	162,000
Current Assets	29,390,000	29,780,000	31,770,000	27,273,000
Other Current Assets	1,502,000	1,940,000	1,509,000	1,596,000
Restricted Cash		0	55,000	148,000	140,000
Inventory	2,690,000	2,557,000	2,662,000	2,339,000
Other Inventories				-484,000	-909,000
Finished Goods				509,000	543,000
Work In Process				1,850,000	2,111,000
Raw Materials				464,000	350,000
Receivables	14,525,000	14,424,000	15,264,000	13,937,000
Other Receivables	2,013,000	2,120,000	2,455,000	2,239,000
Taxes Receivable	2,920,000	3,292,000	3,927,000	3,547,000
Accounts Receivable	9,592,000	9,012,000	8,882,000	8,151,000
Allowance For Doubtful Accounts Receivable	-1,778,000	-945,000	-669,000	-697,000
Gross Accounts Receivable	11,370,000	9,957,000	9,551,000	8,848,000
Cash Cash Equivalents And Short Term Investments	10,673,000	10,859,000	12,280,000	9,253,000
Other Short Term Investments	464,000	513,000	816,000	130,000
Cash And Cash Equivalents	10,209,000	10,346,000	11,464,000	9,123,000

Cash Flow

	2025	2024	2023	2022	2021
Free Cash Flow	12,845,000	13,942,000	12,651,000	11,948,000
Repurchase Of Capital Stock	0	0	-5,155,000	-8,001,000
Repayment Of Debt	-10,940,000	-5,873,000	-3,999,000	-11,431,000
Issuance Of Debt	5,765,000	15,969,000	4,455,000	6,120,000
Capital Expenditure	-1,311,000	-1,248,000	-1,209,000	-1,118,000
End Cash Position	10,218,000	10,347,000	11,519,000	9,325,000
Beginning Cash Position	10,347,000	11,519,000	9,325,000	14,316,000
Effect Of Exchange Rate Changes	195,000	-137,000	45,000	-33,000
Changes In Cash	-324,000	-1,035,000	2,149,000	-4,958,000
Financing Cash Flow	-10,348,000	5,127,000	-9,416,000	-16,962,000
Cash Flow From Continuing Financing Activities	-10,348,000	5,127,000	-9,416,000	-16,962,000
Net Other Financing Charges					641,000
Proceeds From Stock Option Exercised	-128,000	-106,000	27,000	984,000
Cash Dividends Paid	-5,045,000	-4,863,000	-4,744,000	-4,634,000
Common Stock Dividend Paid	-5,045,000	-4,863,000	-4,744,000	-4,634,000
Net Common Stock Issuance	0	0	-5,155,000	-8,001,000
Common Stock Payments	0	0	-5,155,000	-8,001,000
Net Issuance Payments Of Debt	-5,175,000	10,096,000	456,000	-5,311,000
Net Short Term Debt Issuance	25,000	86,000	-120,000	194,000
Short Term Debt Payments	0	-3,000,000	-120,000	0
Short Term Debt Issuance	25,000	3,086,000	0	194,000
Net Long Term Debt Issuance	-5,200,000	10,010,000	576,000	-5,505,000
Long Term Debt Payments	-10,940,000	-2,873,000	-3,879,000	-11,431,000
Long Term Debt Issuance	5,740,000	12,883,000	4,455,000	5,926,000
Investing Cash Flow	-4,132,000	-21,352,000	-2,295,000	-1,062,000
Cash Flow From Continuing Investing Activities	-4,132,000	-21,352,000	-2,295,000	-1,062,000
Net Investment Purchase And Sale	52,000	618,000	-826,000	3,037,000
Sale Of Investment	2,052,000	1,387,000	948,000	6,629,000
Purchase Of Investment	-2,000,000	-769,000	-1,774,000	-3,592,000
Net Business Purchase And Sale	-2,873,000	-20,722,000	-260,000	-2,981,000
Sale Of Business	1,071,000	1,099,000	909,000	1,305,000
Purchase Of Business	-3,944,000	-21,821,000	-1,169,000	-4,286,000
Capital Expenditure Reported	-1,311,000	-1,248,000	-1,209,000	-1,118,000
Operating Cash Flow	14,156,000	15,190,000	13,860,000	13,066,000
Cash Flow From Continuing Operating Activities	14,156,000	15,190,000	13,860,000	13,066,000
Change In Working Capital	-455,000	810,000	-1,914,000	-2,229,000
Change In Other Working Capital	30,000	2,108,000	237,000	-183,000
Change In Payables And Accrued Expense	-6,000	-1,076,000	-405,000	-1,314,000
Change In Payable	-6,000	-1,076,000	-405,000	-1,314,000
Change In Account Payable	-2,000	184,000	198,000	109,000
Change In Tax Payable	-4,000	-1,260,000	-603,000	-1,423,000
Change In Income Tax Payable	-4,000	-1,260,000	-603,000	-1,423,000
Change In Inventory	-184,000	-486,000	-751,000	-69,000
Change In Receivables	-295,000	264,000	-995,000	-663,000
Other Non Cash Items	4,304,000	13,467,000	1,213,000	1,038,000
Stock Based Compensation	553,000	507,000	518,000	457,000
Asset Impairment Charge	1,098,000	2,963,000	255,000	179,000
Deferred Tax	-965,000	-2,089,000	-3,288,000	-2,738,000
Deferred Income Tax	-965,000	-2,089,000	-3,288,000	-2,738,000
Depreciation Amortization Depletion	4,011,000	9,600,000	9,760,000	10,276,000
Depreciation And Amortization	4,011,000	9,600,000	9,760,000	10,276,000
Operating Gains Losses	-1,445,000	-1,135,000	-724,000	-262,000
Pension And Employee Benefit Expense					35,000
Earnings Losses From Equity Investments	-280,000	-16,000	160,000	801,000
Gain Loss On Sale Of Business	-1,165,000	-1,119,000	-884,000	-1,063,000
Net Income From Continuing Operations	7,055,000	-8,933,000	8,040,000	6,345,000

These metrics estimate what Bristol-Myers Squibb Company is worth based on its fundamentals — independent of what the market currently prices it at. Graham's Fair Value and NCAV are conservative floors rooted in 1930s–60s principles. EPV assumes zero growth. None are price targets — they are reference points for judging whether the current price offers a margin of safety.

Graham's Fair Value

$26.54

Margin of Safety

Market Cap ÷ Company Value

3.31

P/B Ratio

6.34

Warren's Owner Earnings

$12.4B

Latest fiscal year

Graham's 7 Criteria

Defensive Investor Checklist

2/7 — Speculative Investor

✅ Adequate Size

$48.2B

vs > $1.5B revenue

❌ Strong Financial Condition

1.26x

vs Current Ratio > 2.0x

❌ Earnings Stability

1 loss years (4 yrs data)

vs No negative EPS years

✅ Dividend Record

4.29%

vs Uninterrupted dividends

❌ Earnings Growth

+17.3% EPS growth

vs > 33% EPS growth

❌ Moderate P/E Ratio

16.1x

vs P/E ≤ 15.0x

❌ Moderate Price-to-Book

6.34x P/B (P/E×P/B: 101.7)

vs P/B ≤ 1.5x | P/E × P/B ≤ 22.5

Net Current Asset Value

$-20.64

Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign.

"Buy at two-thirds of net current assets." — Graham

Earnings Power Value

$74.69

Per share, no-growth floor. Compare to current price.

Cash Flow Analysis

Metric	2025	2024	2023	2022	2021
Capital Expenditure % of Net Income	18.6%	N/A	15.1%	17.7%	N/A
Repurchase of Capital Stock	$0M	$0M	-$5.2B	-$8.0B	N/A
Free Cash Flow	$12.8B ▼	$13.9B ▲	$12.7B ▲	$11.9B •	N/A •
Warren's Owner Earnings	$12.4B	$1.9B	$19.0B	$17.7B	N/A

Peers & Industry

No auto-detected peers for Drug Manufacturers - General. You can manually compare BMY against any stock using the Compare tool.

"The management of a business is its most important single factor — more important than market position, patents, or financial structure."

— Benjamin Graham

Capital Allocation & Alignment

Insider Ownership

0.09%

Low — management has little skin in the game

Return on Equity (ROE)

38.2%

Excellent — management generates strong returns on equity

Return on Assets (ROA)

7.8%

Strong — management uses assets efficiently

Debt Trend YoY

-7.9% YoY

Debt is declining — management is deleveraging

Leadership Team

Christopher Boerner Ph.

CEO & Chairman

Age 54

Pay: $5,818,520

0.082% of net income

David Elkins

Executive VP & CFO

Age 57

Pay: $3,196,077

0.045% of net income

Top Institutional Holders

Institution	% Owned	Shares
Vanguard Group Inc	9.73%	198,727,768
Blackrock Inc.	8.66%	176,825,406
State Street Corporation	4.80%	97,980,438
JPMORGAN CHASE & CO	3.69%	75,367,653
Charles Schwab Investment Management, Inc.	3.49%	71,322,392
Geode Capital Management, LLC	2.58%	52,638,346
NORGES BANK	1.77%	36,100,698
Morgan Stanley	1.39%	28,348,637

Risk Analysis

Beta (Market Risk)

0.26

Low volatility — more stable than the market

Short Interest

1.6% of float

Low short interest — market is not heavily bearish

Debt-to-Equity

2.31x

High leverage — significant financial risk

Current Ratio

1.42x

Adequate liquidity

52-Week Price Range

Low: $42.52 Current: $57.33 High: $62.89

Currently at 73% of 52-week range

360investing